Urocanic acid - Herantis Pharma

Drug Profile

Urocanic acid - Herantis Pharma

Alternative Names: Ci-UCA Emulsion Cream; Cis-UCA; Cis-UCA Eye Drops; ProtoCure; UCA-001; UCA-002

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioCis Pharma
  • Developer Herantis Pharma
  • Class Acrylates; Antineoplastics; Imidazoles; Immunotherapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Atopic dermatitis; Dry eyes

Highest Development Phases

  • Phase II Dry eyes
  • Suspended Atopic dermatitis
  • No development reported Bladder cancer; Interstitial cystitis
  • Discontinued Plaque psoriasis

Most Recent Events

  • 07 Feb 2017 Phase-II development for Dry eyes is ongoing in USA (Ophthalmic, drops)
  • 15 Dec 2016 Biomarkers information updated
  • 12 Oct 2015 Urocanic acid - Herantis Pharma is available for licensing-http://herantis.com/wp-content/uploads/2015/09/Herantis_NLS_2015.pdf
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top